Science and Research

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

BACKGROUND: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study, we hypothesized that Ruxo's mode of action in this condition is reflected by changes in the peripheral blood proteome. METHODS: This study included 11 COVID-19 patients, who were treated at our center's Intensive Care Unit (ICU). All patients received standard-of-care treatment and n = 8 patients with ARDS received Ruxo in addition. Blood samples were collected before (day 0) and on days 1, 6, and 10 of Ruxo treatment or, respectively, ICU admission. Serum proteomes were analyzed by mass spectrometry (MS) and cytometric bead array. RESULTS: Linear modeling of MS data yielded 27 significantly differentially regulated proteins on day 1, 69 on day 6 and 72 on day 10. Only five factors (IGLV10-54, PSMB1, PGLYRP1, APOA5, WARS1) were regulated both concordantly and significantly over time. Overrepresentation analysis revealed biological processes involving T-cells only on day 1, while a humoral immune response and complement activation were detected at day 6 and day 10. Pathway enrichment analysis identified the NRF2-pathway early under Ruxo treatment and Network map of SARS-CoV-2 signaling and Statin inhibition of cholesterol production at later time points. CONCLUSION: Our results indicate that the mechanism of action of Ruxo in COVID-19-ARDS can be related to both known effects of this drug as a modulator of T-cells and the SARS-CoV-2-infection.

  • Völkel, S.
  • Tarawneh, T. S.
  • Sacher, L.
  • Bhagwat, A. M.
  • Karim, I.
  • Mack, H. I. D.
  • Wiesmann, T.
  • Beutel, B.
  • Hoyer, J.
  • Keller, C.
  • Renz, H.
  • Burchert, A.
  • Neubauer, A.
  • Graumann, J.
  • Skevaki, C.
  • Mack, E. K. M.

Keywords

  • Covid-19
  • Ruxolitinib
  • SARS-CoV-2
  • acute respiratory distress syndrome
  • proteomics
Publication details
DOI: 10.3389/fmed.2023.1176427
Journal: Front Med (Lausanne)
Pages: 1176427 
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: UMR
Access-Number: 37293294

DZL Engagements

chevron-down